New insider activity at Incyte ( (INCY) ) has taken place on December 3, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EVP & Chief Medical Officer Steven H Stein recently sold 39,757 shares of Incyte stock, amounting to a total transaction value of $4,068,607.
Spark’s Take on INCY Stock
According to Spark, TipRanks’ AI Analyst, INCY is a Outperform.
Incyte’s strong financial performance and positive earnings call sentiment are the primary drivers of its high score. The company’s robust profitability, minimal leverage, and strategic R&D investments position it well for future growth. Technical indicators suggest bullish momentum, although caution is advised due to overbought signals. The valuation is fair, supporting the company’s growth potential.
To see Spark’s full report on INCY stock, click here.
More about Incyte
YTD Price Performance: 45.89%
Average Trading Volume: 2,128,075
Technical Sentiment Signal: Buy
Current Market Cap: $19.91B